Prime Capital Investment Advisors LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 22.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 126,284 shares of the biopharmaceutical company's stock after selling 37,464 shares during the quarter. Prime Capital Investment Advisors LLC's holdings in Pfizer were worth $3,061,000 at the end of the most recent quarter.
A number of other institutional investors also recently bought and sold shares of PFE. GKV Capital Management Co. Inc. acquired a new position in Pfizer in the first quarter valued at $27,000. North Capital Inc. acquired a new position in Pfizer in the first quarter valued at $28,000. Bayforest Capital Ltd acquired a new position in Pfizer in the first quarter valued at $28,000. Horizon Financial Services LLC acquired a new position in Pfizer in the first quarter valued at $35,000. Finally, WPG Advisers LLC acquired a new position in Pfizer in the first quarter valued at $35,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Stock Down 0.6%
PFE stock opened at $26.27 on Wednesday. The company has a market cap of $149.36 billion, a P/E ratio of 13.97, a P/E/G ratio of 0.86 and a beta of 0.55. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The company's 50-day moving average price is $24.76 and its 200 day moving average price is $24.14. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.
Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm's revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several analysts have recently weighed in on PFE shares. Wall Street Zen downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a report on Sunday, September 28th. Citigroup lifted their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Bank of America lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a report on Friday, October 3rd. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a report on Saturday, September 27th. Finally, Morgan Stanley lifted their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer has an average rating of "Hold" and a consensus price target of $28.41.
Read Our Latest Stock Report on Pfizer
Pfizer Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
